Drug intelligence / Profile preview

PR591

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes

Overview

PR591 is a preclinical asset developed by Protomer Technologies, which was acquired by Eli Lilly. It is an engineered insulin analog designed as a small protein therapeutic. This drug is glucose-responsive, meaning it is engineered to automatically activate in high-glucose conditions. Its primary aim is to reduce the risk of hypoglycemia for patients with both type 1 and type 2 diabetes by providing a more controlled insulin response.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on PR591.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PR591.

Explore the full profile